Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 29, 2017

View Archived Issues

ZPIV demonstrates safety and immunogenicity in preliminary analysis of three phase I studies

CStone seeks Australian clinical trial approval to begin studies of CS-1003 and CS-3006

Patient recruitment ongoing in phase II trial of CR-6086

Phase I study of C188-9 enrolling patients with advanced cancer

FDA approves expanded indication for Procysbito to include children 1 year of age and older

Treatment with CRISPR-Cas9 improves motor function and extends survival in mouse model of ALS

Descartes-08 cells demonstrate promising antitumor effect in preclinical models of multiple myeloma

Fervent Pharmaceuticals submits IND in U.S. for FP-101

CD229 CAR T cells demonstrate strong cytotoxic activity, selectivity in models of multiple myeloma

Phase III EMBRACA study meets primary endpoint of PFS with talazoparib over chemotherapy

Caveolin-1 as a potential novel target with antimetastatic function in macrophages

GAK as a potential new therapeutic target for FBXW7-deficient tumors

TherapeuticsMD submits NDA for TX-001-HR to treat menopausal vasomotor symptoms

Odonate Therapeutics announces initiation of phase III CONTESSA study

BiondVax Pharmaceuticals planning phase III study of universal flu vaccine

FDA grants priority review to Epidiolex NDA, GW Pharmaceuticals submits MAA in Europe

Brazilian approval for Biocon and Mylan's trastuzumab biosimilar

Genexine signs licensing agreement with I-Mab for HyLeukin in Greater China

HTG Molecular Diagnostics in new master collaboration agreement with Merck KGaA

FDA approves Dermapace System to treat diabetic foot ulcers

Gilead Sciences patents farnesoid X receptor agonists

Infinity Pharmaceuticals describes PI3Kgamma/delta inhibitors

Janssen Biotech reports development of GM-CSF variants for treatment of IBD

Medshine Discovery patent describes beta-lactamase inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...